GSK PLC

Latest Results (18.10.2025):

In the second quarter of 2025, GSK PLC delivered a robust financial performance, underpinned by strong growth in Specialty Medicines and Vaccines. The company achieved increased sales, operating profit, and earnings per share, demonstrating its continued resilience and strategic focus in key business segments.

Sales Growth

Total sales for Q2 2025 reached £8.0 billion, marking a 1% increase on an AER basis and a 6% increase on a CER basis. Specialty Medicines significantly contributed to this growth, driving overall performance.

Specialty Medicines Performance

Sales in Specialty Medicines surged by 15% to £3.3 billion. Notably, Oncology sales skyrocketed by 42% to £0.5 billion, while Respiratory, Immunology & Inflammation and HIV segments grew by 10% and 12%, reaching £1.0 billion and £1.9 billion respectively.

Vaccines Growth

Vaccines sales increased by 9% to £2.1 billion. The Meningitis vaccines segment saw a remarkable 22% growth, while Shingrix and Arexvy grew by 6% and 13%, achieving sales of £0.9 billion and £0.1 billion respectively.

General Medicines

General Medicines experienced a slight decline, with sales decreasing by 6% to £2.6 billion. However, Trelegy within this segment showed resilience, increasing sales by 4% to £0.8 billion.

Profit and Earnings Growth

GSK reported a total operating profit increase of 33% and a total EPS growth of 35%, driven by lower CCL charges and tempered by intangible asset impairments. Core operating profit rose by 12%, and Core EPS by 15%, reflecting robust growth in Specialty Medicines and Vaccines, alongside higher royalty income.

Cash Flow

The company generated £2.4 billion from operations, with a free cash flow of £1.1 billion. This strong cash generation underpins GSK's ongoing investment in R&D and shareholder return initiatives.

Pipeline and R&D Progress

GSK continues to advance its pipeline with five major new product approvals expected in 2025, including significant developments in Oncology and Respiratory treatments. The company has made substantial investments in late-stage development programs, positioning itself for future growth.

Shareholder Returns

GSK reaffirmed its commitment to shareholder returns, declaring a dividend of 16p for Q2 2025 and expecting a full-year dividend of 64p. Additionally, £822 million was allocated towards the £2 billion share buyback programme in H1 2025.

Guidance for 2025

Looking ahead, GSK is confident in achieving the top end of its 2025 financial guidance. The company expects turnover growth of 3% to 5%, core operating profit growth of 6% to 8%, and Core EPS growth of 6% to 8%, all at constant exchange rates.